Atlas FDA

UroVysion Bladder Cancer Kit

FDA premarket approval P030052/S030 · decided 2026-02-18

Approval details

PMA number
P030052
Supplement
S030
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
UroVysion Bladder Cancer Kit
Applicant
Abbott Molecular
Date received
2026-01-21
Decision date
2026-02-18
Days to decision
28 days
Decision code
OK30
Advisory committee
Pathology
Expedited review
No
Location
Des Plaines, IL
Statement
implementation of a secondary packaging process

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
simpli-COLLECT STI Test (K243410)Abbott Molecular2025-01-30
Alinity m SARS-CoV-2 AMP Kit (09N78-096); Alinity m SARS-CoV-2 CTRL Kit (09N78-086) (K241580)Abbott Molecular2024-12-06